Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 8/20 | 0.90 |
| ▸ | MEN1 | O00255 | 7/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.81 |
| ▸ | GBA1 | P04062 | 2/20 | 0.81 |
| ▸ | ATM | Q13315 | 1/20 | 0.81 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.73 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | USP1 | O94782 | 2/20 | 0.66 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.66 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.65 |
| ▸ | USP2 | O75604 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2591972 | 0.94 | PDE5A (1.00) | PDE5AMEN1KMT2AGBA1ATM | |
| SCHEMBL1063668 | 0.92 | PDE5A (0.81) | PDE5AMEN1KMT2AGBA1ATM | |
| SCHEMBL12176337 | 0.92 | PDE5A (0.85) | PDE5AMEN1KMT2AGBA1ATM | |
| SCHEMBL1083763 | 0.90 | PDE5A (1.00) | PDE5AMEN1KMT2AGBA1ATM | |
| SCHEMBL14262933 | 0.89 | CYP1A2 (0.84) | PDE5AMEN1KMT2AGBA1ATM | |
| SCHEMBL4867611 | 0.88 | PDE5A (0.73) | PDE5AMEN1KMT2AGBA1ATM | |
| SCHEMBL4866252 | 0.88 | PDE5A (0.78) | PDE5AMEN1KMT2AGBA1ATM | |
| SCHEMBL12176338 | 0.88 | PDE5A (0.78) | PDE5AMEN1KMT2AGBA1ATM | |
| SCHEMBL1084183 | 0.87 | MEN1 (0.89) | PDE5AMEN1KMT2AGBA1ATM | |
| SCHEMBL28805458 | 0.86 | PDE5A (0.76) | PDE5AMEN1KMT2AGBA1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | claimed |
| JP-2008526734-A | — | — | 2008-07-24 | — | — | JP | claimed |
| EP-1844023-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2007-10-17 | — | — | EP | claimed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| CN-103068393-A | Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase | CLEAVE BIOSCIENCES INC CLEAVE | 2013-04-24 | — | — | CN | disclosed |
| EP-2566480-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | California Institute of Technology (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140527-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | CALIFORNIA INSTITUTE OF TECHNOLOGY AND THE UNIVERSITY OF KANSAS (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | disclosed |
| EP-1844023-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | PDE5A 1861/4885MEN1 718/4885KMT2A 1424/4885 |
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | GPR119, GCKR, GLP1R | PDE5A 204/4885MEN1 3837/4885KMT2A 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.